Y. Li

发表

Thresholding of a Continuous Companion Diagnostic Test Confident of Efficacy in Targeted Population

Eloise E Kaizar, J. Hsu, S. Ruberg, 2016 .

The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration

K. Winters, J. Jakubowski, J. Brandt, 2008, Thrombosis and Haemostasis.

Population Pharmacokinetic Analyses to Evaluate the Influence of Intrinsic and Extrinsic Factors on Exposure of Prasugrel Active Metabolite in TRITON‐TIMI 38

E. Antman, E. Braunwald, S. Wiviott, 2009, Journal of clinical pharmacology.

Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial.

R. Kelly, K. Winters, P. Kothare, 2010, Clinical therapeutics.

The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects

K. Winters, P. Kothare, J. Jakubowski, 2010, European Journal of Clinical Pharmacology.

Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo‐controlled trial in patients with type 2 diabetes using metformin

D. Cox, J. Frias, L. Tham, 2019, Diabetes, obesity & metabolism.

OPTIMIZED HUMAN REGULAR U-500 INSULIN TREATMENT IMPROVES β-CELL FUNCTION IN SEVERELY INSULIN-RESISTANT PATIENTS WITH LONG-STANDING TYPE 2 DIABETES AND HIGH INSULIN REQUIREMENTS.

J. Rosenstock, A. Mari, Y. Li, 2015, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Effect of Atorvastatin on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Subjects

K. Winters, C. Ernest, J. Jakubowski, 2008, Pharmacotherapy.

Genetic variation of GPLD1 associates with serum GPI-PLD levels: a preliminary study.

G. Eckert, R. Considine, X. Xuei, 2012, Biochimica et biophysica acta.

Relationship Between Exposure to Prasugrel Active Metabolite and Clinical Outcomes in the TRITON‐TIMI 38 Substudy

Junxiang Luo, C. Ernest, R. Wrishko, 2012, Journal of clinical pharmacology.

Integrated Analysis of Pharmacokinetic Data Across Multiple Clinical Pharmacology Studies of Prasugrel, a New Thienopyridine Antiplatelet Agent

K. Winters, C. Ernest, N. Farid, 2011, Journal of clinical pharmacology.

Abstract 4001: Relationship between Exposure to the Prasugrel Active Metabolite with TIMI Major/Minor Bleeding in TRITON-TIMI 38

E. Antman, S. Wiviott, C. Ernest, 2008 .

Effect of Age on the Pharmacokinetics and Pharmacodynamics of Prasugrel during Multiple Dosing

K. Winters, C. Ernest, R. Wrishko, 2009, Drugs & aging.

Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects

K. Winters, J. Jakubowski, J. Brandt, 2008, Platelets.

The Onset of Inhibition of Platelet Aggregation With Prasugrel Compared With Clopidogrel Loading Doses Using Gatekeeping Analysis of Integrated Clinical Pharmacology Data

M. Effron, P. Kulkarni, Junxiang Luo, 2011, Journal of cardiovascular pharmacology.

A Comparison of the VerifyNow P2Y12 Point-of-Care Device and Light Transmission Aggregometry to Monitor Platelet Function with Prasugrel and Clopidogrel: An Integrated Analysis

Junxiang Luo, K. Winters, J. Jakubowski, 2010, Journal of cardiovascular pharmacology.

A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry

K. Winters, J. Jakubowski, J. Brandt, 2007, Thrombosis and Haemostasis.

Dose-Dependent Inhibition of Human Platelet Aggregation by Prasugrel and its Interaction With Aspirin in Healthy Subjects

K. Winters, G. Weerakkody, J. Jakubowski, 2007, Journal of cardiovascular pharmacology.

Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)

E. Bonora, D. Cox, J. Frias, 2021, Diabetes Care.

Absence of "rebound" platelet hyperreactivity following cessation of prasugrel

K. Winters, J. Jakubowski, Y. Li, 2011, Thrombosis and Haemostasis.

Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel

K. Winters, G. Weerakkody, J. Brandt, 2008, Journal of clinical pharmacology.

Increased Active Metabolite Formation Explains the Greater Platelet Inhibition With Prasugrel Compared to High-dose Clopidogrel

K. Winters, C. Ernest, J. Jakubowski, 2007, Journal of cardiovascular pharmacology.

TWO TREATMENT APPROACHES FOR HUMAN REGULAR U-500 INSULIN IN PATIENTS WITH TYPE 2 DIABETES NOT ACHIEVING ADEQUATE GLYCEMIC CONTROL ON HIGH-DOSE U-100 INSULIN THERAPY WITH OR WITHOUT ORAL AGENTS: A RANDOMIZED, TITRATION-TO-TARGET CLINICAL TRIAL.

C. Wysham, R. Arakaki, Y. Li, 2015, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Effect of Linagliptin on Glycemic Control in Chinese Patients with Newly-Diagnosed, Drug-Naïve Type 2 Diabetes Mellitus: A Randomized Controlled Trial

Wenjun Wu, F. Shen, Xiong Chen, 2015, Medical science monitor : international medical journal of experimental and clinical research.

Inhibition of platelet aggregation with prasugrel and clopidogrel: An integrated analysis in 846 subjects

K. Winters, J. Jakubowski, J. Brandt, 2009, Platelets.

Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel

K. Winters, N. Farid, Y. Li, 2008, Current medical research and opinion.

Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end‐stage renal disease

K. Winters, C. Ernest, R. Wrishko, 2009, Journal of clinical pharmacy and therapeutics.

Inhibition of platelet aggregation with prasugrel and clopidogrel: An integrated analysis in 846 subjects

K. Winters, J. Jakubowski, J. Brandt, 2009, Platelets.

Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver disease

K. Winters, C. Ernest, N. Farid, 2009, Journal of clinical pharmacy and therapeutics.

Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects

K. Winters, C. Ernest, J. Jakubowski, 2009, Current medical research and opinion.